Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.73 |
| ▸ | HTR2A | P28223 | 5/20 | 0.73 |
| ▸ | HTR7 | P34969 | 4/20 | 0.73 |
| ▸ | HTR6 | P50406 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perospirone SCHEMBL30061058 | 1.00 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL120579 | 1.00 | HTR1A (1.00) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL29846330 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1155757 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28506465 | 0.99 | HTR1A (0.98) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1651000 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL1865565 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL5435087 | 0.98 | HTR1A (0.96) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| Perospirone SCHEMBL28054292 | 0.94 | HTR1A (0.89) | HTR1ALMNACHRM2ADRA2ACHRM1 | |
| SCHEMBL7283429 | 0.88 | HTR1A (0.79) | HTR1ALMNACHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1238676-B1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1238676-A1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| EP-0196096-B1 | IMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-04-22 | — | — | EP | claimed |
| US-4745117-A | NEUROLEPTIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-05-17 | — | — | US | claimed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1238676-B1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | PFIZER PROD INC (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1238676-A1 | Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HTR1A 477/4885LMNA 3003/4885CHRM2 670/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885LMNA 3909/4885CHRM2 257/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | HTR1A 1881/4885LMNA 2321/4885CHRM2 340/4885 |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | SLC6A3, OXTR, OPRD1 | HTR1A 9/4885LMNA 3562/4885CHRM2 1018/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HTR1A 477/4885LMNA 3003/4885CHRM2 670/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | HTR1A 926/4885LMNA 1728/4885CHRM2 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.